Navigation Links
Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division
Date:2/8/2010

LAWRENCEVILLE, N.J., Feb. 8 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced today that Michael H. Richardson has joined the company as Vice President, Commercial Operations for the newly formed Orphan Drug Business Unit. Donald A. Fishbein assumes the same role for the Ophthalmic Business Unit. A wholly owned subsidiary of Princeton Pharma Holdings LLC, Aton is focused on the development and commercialization of unique products in ophthalmology and orphan diseases.

Mr. Richardson holds responsibility of the company's orphan drug portfolio, which includes well-established specialty pharmaceuticals treating a range of rare and life-threatening conditions (Mephyton®, Edecrin®, Sodium Edecrin®, Cuprimine®, Syprine®, Demser®).  

Mr. Richardson possesses nearly 20 years of experience in pharmaceutical marketing, sales, product planning and business development. Prior to joining Aton, he was a Group Director of Marketing and Senior Director of Worldwide Product Planning for Cephalon. In those roles, Mr. Richardson was responsible for the successful launch of multiple products.

"With both product and corporate management experience, Michael Richardson brings tremendous commercial leadership to Aton Pharma," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "He is well rounded in all aspects of pharmaceutical marketing and preparing new products for launch. This experience will provide tremendous value to the company as we expand our orphan drug portfolio."

Prior to Cephalon, Mr. Richardson was a Director of Global Strategic Marketing at Johnson & Johnson where he worked on optimizing the life cycle of several strategic products. Also at Johnson & Johnson he served in New Product Planning. Prior to Johnson & Johnson, Mr. Richardson was in Sales for Merck & Co., Inc. He holds a B.A. degree in Chemistry from West Virginia University and a M.B.A. from the Fuqua School of Business at Duke University.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of products, with sales in over 30 countries, focuses on ophthalmic diseases and orphan conditions. For more information, see www.atonrx.com.

SOURCE Aton Pharma, Inc.

RELATED LINKS
http://www.atonrx.com

'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance
2. Octapharma Accepting Applications for Research Grants Through March 31
3. Two Long-Term Care Organizations Select Remedi SeniorCare for Pharmacy Services
4. Possible pharmacological target(s) identified in pediatric OSA
5. Six Key Areas of Learning for Pharmaceutical and Healthcare Marketing in 2010
6. Frost & Sullivan Ghanaian Pharmaceutical Industry Innovation & Advancement Award Conferred on LaGray Chemical Company
7. Viscira Expands Interactive Solutions to Reduce Marketing Expenses for Pharmaceutical Companies in Challenging Economic Times
8. Nutra Pharma Announces Fourth Quarter Sales for its Over-the-Counter (OTC) Pain Reliever, Cobroxin
9. Pharmalink Regulatory Affairs Consulting Firm Opens New Offices in Washington, DC and Hartford, CT
10. Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments
11. Standard Methods Miss 50% of Pharmaceutical Key Opinion Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... 001 and its sugar-free alternative VW+ 002. The drinks have been produced in ... optimal conditions to perform during your workout. , After a successful launch in ...
(Date:1/20/2017)... ... , ... “The Angel”: a heartwarming and earnest tale of faith and ... children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a former professional ... writer. , When asked of her new book, Marjorie says, “‘The Angel’ was written ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “I Forgive You”: a fine examination ... “I Forgive You” is the creation of published author, Stephen Miller, who, for over ten ... has gracefully given to him. Born in Trinidad and Tobago, he has been serving the ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: ... published author, Sara Seymour, who lives in Lafayette, Indiana where she works in a ... iced coffees and writes. , Published by Christian Faith Publishing, Sara Seymour’s new book ...
(Date:1/20/2017)... ... ... is God’s Lighthouse”: a moving and colorful collection of prayers that reminds readers ... author, Gene Gaapf, a retired truck driver, and a long-time writer, whose published works ... school and have many different titles,” Gaapf mentions about his different works. “I am ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017  Faruqi & Faruqi, LLP, a ... ("KemPharm" or the "Company") (NASDAQ: KMPH ) of ... and certain officers and directors and underwriters of the Company,s ... the role of lead plaintiff. The lawsuit has ... Court for Johnson County on behalf ...
(Date:1/20/2017)... Research and Markets has announced the ... Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company Analysis ... ... Aids Market Sales Volume, Company Analysis and Forecast to 2022 ... industry. The growing prevalence of hearing impairment coupled ...
(Date:1/20/2017)... Stock-Callers.com today evaluates the following Drug Manufacturers equities: ... A/S (NYSE: NVO ), Sucampo Pharmaceuticals Inc. (NASDAQ: ... PTX ). These stocks belong to the Healthcare ... finishing near its session lows. As per a NASDAQ report, ... of health care companies in the S&P 500 also were ...
Breaking Medicine Technology: